NCT07422857招募中3 期
Phase III Multicenter Clinical Trial Evaluating the Use of [18F]-APN-1607 Injection in Positron Emission Tomography in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
JYAMS PET Research & Development Limited2 个研究点 分布在 1 个国家目标入组 316 人开始时间: 2026年1月22日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 316
- 试验地点
- 2
- 主要终点
- Evaluate the effectiveness of visual reading results of [18 F]-APN-1607 injection PET imaging in detecting tau NFTs（Neurofibrillary Tangles）
研究概览
简要总结
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must be able to understand and voluntarily sign a written informed consent form (ICF);
- •Age ≥ 50 years, regardless of gender;
- •Subjects with HV, MCI, and AD should meet the clinical diagnostic criteria
- •Can tolerate brain MRI and PET imaging examinations;
- •For women of potential fertility (not yet menopausal or within 2 years of menopause), effective contraception must be used during the study and for 3 months after the study (effective contraception refers to sterilization, intrauterine hormonal devices, condoms, birth control pills, abstinence, or partner vasectomy, etc.); male participants should agree to use contraception during the study and for 3 months after the study.
排除标准
- •Specific clinical phenotypes of atypical AD as defined in the 2014 IWG-2 criteria
- •Possible presence of frontotemporal degeneration (FTLD), characterized by progressive psych behavioral abnormalities and executive dysfunction，Characterized primarily by impairment and language function, progressive aphasia
- •The core symptoms of Lewy body dementia include fluctuating cognitive changes accompanied by significant attention and arousal abnormalities, recurrent typical visual hallucinations, and spontaneous symptoms of Parkinson's syndrome;
- •Currently suffering from significant mental illness. Subjects with accompanying psychiatric symptoms need to be carefully evaluated by the researchers to determine whether they can complete the imaging process;
- •Brain structural abnormalities confirmed by MRI, such as large strokes (infarct area greater than 4 cm) or intracranial space-occupying lesions;
- •Suffering from claustrophobia or unable to tolerate imaging procedures for other reasons;
- •History of alcohol or drug abuse/dependency;
- •Hypersensitivity to the investigational drug or any of its components;
- •Currently pregnant or breastfeeding;
- •Received non-vaccine investigational treatment for Alzheimer's disease or other dementia within 3 months prior to screening, or received passive immunotherapy (antibody) for the treatment of Alzheimer's disease or other dementia within 6 months prior to screening, or previously received a vaccine for the treatment of Alzheimer's disease or other dementia; or participated in other new drug clinical trials within 30 days prior to enrollment;
- •At present, the researcher suffers from serious diseases, such as infectious diseases, infectious diseases, endocrine or metabolic diseases, as well as serious cardiac function, liver function, lung function, and kidney function damage, and believes that participation in this study will have adverse effects on the subject or the research results
- •Currently suffering from a disease or factor that causes QT interval prolongation, including torsades de pointes, QT prolongation syndrome, hyperkalemia, hypocalcemia, or taking medications that can prolong the QT interval, such as quinidine, amiodarone, or sotalol
- •There are other situations that researchers consider unsuitable for participating in the experiment.
研究组 & 干预措施
Alzheimer's Disease
Experimental
AD subjects will undergo PET imaging using [18F]APN-1607.
干预措施: [18F]-APN-1607 (Drug)
Mild Cognitive Impairment Due to Alzheimer's Disease
Experimental
MCI subjects will undergo PET imaging using [18F]APN-1607.
干预措施: [18F]-APN-1607 (Drug)
Healthy Volunteers
Other
Healthy control subjects will undergo PET imaging using [18F]APN-1607.
干预措施: [18F]-APN-1607 (Drug)
结局指标
主要结局
Evaluate the effectiveness of visual reading results of [18 F]-APN-1607 injection PET imaging in detecting tau NFTs（Neurofibrillary Tangles）
时间窗: 15 months
Sensitivity and specificity of PET imaging visual interpretation results of \[ 18 F\]-APN-1607 injection compared with true standards
次要结局
- Assessment of [18 F]-APN-1607 Uptake Patterns by Regional SUVR Values and the capability in differentiating different groups(15 months)
- Safety and Tolerability Profile Measured by Adverse Events (AEs)(15 months)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.Cholangiocarcinoma2023-507938-24-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)81
尚未招募
不适用
HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDGMultiple CancersMultiple Indications CancerFeasibility StudiesNCT07295171British Columbia Cancer Agency27
尚未招募
2 期
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE TrialBladder CancerNCT07257718Chiti Arturo262
招募中
2 期
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active SurveillanceProstatic NeoplasmsProstate CancerNCT07285057Icahn School of Medicine at Mount Sinai120
招募中
不适用
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant TumorsPancreatic CancerGastric CancerEsophageal CancerNCT07301814Union Hospital, Tongji Medical College, Huazhong University of Science and Technology56